Does Cancer Cause High or Low White Blood Cell Counts?

Cancer can drive white blood cell counts in both directions, sometimes dramatically high and sometimes dangerously low, depending on the type of cancer involved, whether it starts in the blood-forming system or elsewhere, and what treatments are in play. A person with untreated leukemia might walk into a clinic with a white blood cell count several times the normal upper limit, while someone on chemotherapy for breast cancer could see their count plummet to near zero. The relationship between cancer and white blood cells is not a single story but several overlapping ones, and understanding which scenario applies matters for treatment decisions and day-to-day safety.

When Cancer Pushes White Blood Cell Counts Up

The most direct way cancer raises white blood cell counts is when the cancer itself originates in the bone marrow or lymphatic system. Leukemias are cancers of white blood cells, and in many cases the hallmark feature is an overproduction of abnormal cells that flood the bloodstream. In acute leukemias specifically, between 5% and 30% of adult patients show up with what is called hyperleukocytosis, meaning a white blood cell count above 100,000 cells per cubic millimeter. A healthy adult typically has somewhere between 4,000 and 11,000. Counts that extreme can cause circulation problems on their own, because the sheer volume of cells makes the blood thicker and more sluggish in small vessels.¹

But leukemias are not the only cancers that can inflate white cell counts. Solid tumors, including lung, bladder, stomach, and certain gynecological cancers, sometimes trigger a phenomenon known as a paraneoplastic leukemoid reaction. In these cases the tumor cells themselves secrete a growth factor called G-CSF directly into the bloodstream. G-CSF is the same signal the bone marrow normally uses to ramp up neutrophil production during an infection, so when a tumor pumps it out continuously, the body responds by manufacturing enormous numbers of neutrophils even though no infection is present.² One documented case involved an undifferentiated endometrial sarcoma that produced G-CSF at such high levels that the patient’s neutrophil count mimicked a blood cancer.³

These paraneoplastic reactions create a clinical headache because they look, on a basic blood test, a lot like a blood cancer or a severe infection. Distinguishing the real cause often requires a bone marrow biopsy or further imaging to find the solid tumor. The key clue is often that the white cells themselves look normal under a microscope, which is unusual for leukemia, where the cells are typically immature or abnormal in shape.

When Cancer Pushes White Blood Cell Counts Down

Even without any treatment, certain cancers can suppress white blood cell production. Leukemias are again the prime example, but through a different mechanism than the one that raises the count. While leukemia cells multiply out of control, they simultaneously crowd out the normal blood-forming cells in the bone marrow. Research has shown that leukemia cells release substances that inhibit both the supportive stromal cells in the bone marrow and the progenitor cells that would normally develop into healthy white blood cells, red blood cells, and platelets.⁴ The result is paradoxical: a patient’s total white count might be sky-high with leukemia cells, but their functional, infection-fighting white cells are actually depleted. This is why leukemia patients are vulnerable to infections despite having blood that looks packed with white cells.

Any cancer that has spread to the bone marrow, even if it started elsewhere, can also suppress normal production. Metastatic breast cancer, prostate cancer, and lung cancer can all infiltrate the marrow and physically displace the cells responsible for making healthy blood. The outcome on a lab report might be low white counts, low red counts, low platelets, or all three at once.

Treatment Effects Are Often the Biggest Factor

For many people living with cancer, the most significant changes to white blood cell counts come not from the cancer itself but from the treatments used against it. Chemotherapy is designed to kill rapidly dividing cells, and the cells in the bone marrow divide faster than almost any other cell type in the body. That makes them collateral damage in nearly every chemotherapy regimen.

Neutropenia, a dangerously low neutrophil count, is one of the most common and serious side effects of chemotherapy. When neutrophils drop far enough, the body loses its front-line defense against bacteria and fungi. To prevent this, drugs like pegfilgrastim (a long-acting form of G-CSF) are routinely used alongside high-risk chemotherapy regimens. In breast cancer treatment, for instance, pegfilgrastim is a standard prophylactic measure against febrile neutropenia, the combination of fever and dangerously low neutrophils that can rapidly become life-threatening.⁵ Similar approaches are used in gynecological cancers like ovarian cancer, where pegylated G-CSF is recommended for preventing neutropenia during chemotherapy cycles.⁶

Radiation therapy has its own distinct effect on white blood cells. While it does not suppress the bone marrow as broadly as chemotherapy in most cases, radiation can cause a significant drop in lymphocytes, a different category of white blood cell. This radiation-induced lymphopenia is an underappreciated side effect. Radiation can reshape the immune environment around a tumor in ways that help the immune system recognize cancer cells, but the simultaneous loss of lymphocytes can undermine that benefit.⁷ This matters because lymphocytes include the T cells and natural killer cells that are central to the body’s ability to seek out and destroy cancer cells.

Why the Type of White Blood Cell Matters

A standard complete blood count gives you a total white blood cell number, but what really tells the story is the differential, the breakdown of which types of white cells are present and in what proportions. The major players are neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Each responds differently to cancer and its treatments.

Neutrophils are the most abundant type and the ones most affected by chemotherapy. They are the body’s first responders to bacterial infections, and their depletion is what makes febrile neutropenia so dangerous. Lymphocytes, on the other hand, are the cells most affected by radiation and by many immunosuppressive therapies. They are also the cells that immunotherapy drugs like checkpoint inhibitors try to activate against tumors.

The ratio between neutrophils and lymphocytes, often called the neutrophil-to-lymphocyte ratio or NLR, has emerged as a surprisingly useful number in cancer medicine. A large cross-sectional study using data from over a decade of national health surveys found that people with the highest NLR values, above 2.6, had a 20% higher adjusted prevalence of cancer compared to those in the lowest category.⁸ A high NLR typically means the body has shifted toward a more inflammatory, neutrophil-heavy profile and away from the lymphocyte-driven adaptive immune response. It does not diagnose cancer on its own, but it is increasingly used as one piece of the puzzle when evaluating prognosis and treatment response.

What Happens When Neutrophils Drop Too Low

Neutropenia in a cancer patient is not something to watch and wait on. The established clinical guideline, which has held steady for years, is that any cancer patient who develops a fever while neutropenic should receive broad-spectrum antibiotics immediately, covering both gram-positive and gram-negative bacteria. There is no “let’s see how it develops” approach here; the window between a mild fever and a life-threatening bloodstream infection can be startlingly narrow when the immune system is depleted.⁹

If you are going through chemotherapy, this is one of the most practical things to know. A temperature of 100.4°F (38°C) or higher when you know your counts are low warrants an immediate call to your oncology team, day or night. Many cancer centers give patients a thermometer and specific instructions about this threshold before they start their first cycle. The risks of waiting even a few hours are well documented, and this is one area where the clinical community is unequivocal.

The timing of the low point, often called the nadir, varies by chemotherapy drug but typically falls somewhere between seven and fourteen days after a treatment cycle. Some regimens are predictable enough that oncologists can schedule a blood draw around the expected nadir to see just how far the count has dropped and decide whether a growth factor injection is needed to speed recovery.

Blood Counts and Immunotherapy

The rise of immunotherapy has added another layer to the relationship between cancer and white blood cell counts. Checkpoint inhibitors, the drugs that “take the brakes off” the immune system to let it attack tumor cells, depend on the patient having functional lymphocytes to work with. A patient whose lymphocyte count has been hammered by prior radiation or chemotherapy may not respond as well to immunotherapy, which is one reason sequencing treatments properly has become such an active area of research.

Blood cell profiles before starting immunotherapy also carry prognostic information. A systematic review and meta-analysis found that baseline blood cell counts, and ratios derived from them, can predict the likelihood of adverse events during checkpoint inhibitor treatment. Patients with a higher baseline neutrophil-to-lymphocyte ratio had roughly double the odds of experiencing immune-related side effects.¹⁰ This makes intuitive sense: a body that is already in a heightened inflammatory state, reflected by high neutrophils relative to lymphocytes, seems more prone to the kind of overactive immune response that checkpoint inhibitors can sometimes unleash against healthy tissue.

Eosinophils, which are among the least discussed white blood cells in everyday medicine, are also getting more attention in cancer contexts. Elevated eosinophil counts before immunotherapy have been associated with both better treatment response in some cancers and a higher risk of certain immune-mediated side effects. The oncology community is still working out exactly what eosinophil levels mean for treatment planning, but the field is clearly moving toward using the full white cell differential, not just total count, as a decision-making tool.

The Tumor Microenvironment and Neutrophil Recruitment

Beyond the numbers on a blood test, cancer changes the behavior of white blood cells in ways that are not visible on a standard lab report. Tumors actively recruit neutrophils into the tissue surrounding them, creating a population known as tumor-associated neutrophils. These recruited cells can behave very differently from the neutrophils circulating in your blood. The tumor microenvironment essentially reprograms them, and the relationship is a two-way street: the tumor controls neutrophil recruitment, and the neutrophils in turn can either help or hinder tumor growth depending on the signals they receive.¹¹

This duality is one of the more fascinating and frustrating aspects of cancer immunology. Early in tumor development, neutrophils that enter the microenvironment may genuinely fight the cancer, killing tumor cells and sounding alarms for the rest of the immune system. As the tumor evolves, though, it increasingly co-opts these cells. Reprogrammed neutrophils can promote new blood vessel growth into the tumor, suppress the activity of T cells that would otherwise attack cancer cells, and even help tumor cells break free and metastasize. The total white blood cell count on a lab report cannot tell you which of these scenarios is playing out inside a tumor, which is part of why researchers are working on more refined biomarkers.

Interpreting Your Own Blood Work

If you are looking at your own complete blood count and wondering what it means, the honest answer is that the number alone tells you very little without context. A mildly elevated white count is far more likely to reflect an ordinary infection, physical stress, or a medication side effect than cancer. A mildly low count can result from a viral illness, an autoimmune condition, or simply being at the low end of normal variation. Cancer is one possible cause on both ends of the spectrum, but it is rarely the first thing a doctor will suspect unless other signs point in that direction.

When cancer is a possibility, the pattern across multiple blood tests matters more than any single result. A count that is steadily rising over weeks without an obvious infection, or a count that keeps falling without a known cause, will attract more clinical attention than a one-time abnormal reading. The differential breakdown adds further detail. A massive spike in immature-looking white cells, sometimes called blasts, is a red flag for leukemia. A high total count with normal-appearing cells might suggest a paraneoplastic reaction or simply a stubborn infection.

It is also worth knowing that some cancers barely affect white blood cell counts at all, at least not until they are advanced. Many early-stage solid tumors, including common ones like colon, prostate, or early breast cancer, produce no meaningful change in blood counts. A normal complete blood count does not rule out cancer, and an abnormal one does not confirm it. The test is a piece of a much larger clinical picture that includes imaging, biopsies, symptom history, and physical examination.

The G-CSF Paradox in Treatment

One of the odder aspects of cancer treatment is that doctors sometimes deliberately inject the same growth factor, G-CSF, that certain tumors produce as part of their disease process. When chemotherapy tanks a patient’s neutrophil count, synthetic G-CSF drugs like filgrastim or pegfilgrastim are given to stimulate the bone marrow to produce new neutrophils faster. This is the same molecule that a G-CSF-secreting tumor uses to cause a paraneoplastic leukemoid reaction, except here it is being given in a controlled dose for a defined period.

The safety of this approach has been well established across decades of use, and the benefit in preventing febrile neutropenia is clear. But it does create an unusual situation in follow-up blood work: a patient receiving G-CSF after chemotherapy might briefly show very high white cell counts that look alarming if taken out of context. Oncology teams expect this rebound and account for it when interpreting labs, but patients who are monitoring their own blood work at home through a patient portal sometimes get an unpleasant surprise when they see a count in the 30,000 or 40,000 range. In that setting, a temporary spike is the drug doing exactly what it is supposed to do.